Anticytokine therapy in non-rheumatoid arthritis indications in 2009

Current Opinion in Rheumatology

Volumn 21, Issue 3, 2009, Pages 251-255

  Villa Forte, Alexandra ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antitumor necrosis factor alpha therapies; Juvenile idiopathic arthritis; Psoriatic arthritis; Spondyloarthropathies

Indexed keywords

ADALIMUMAB; ATLIZUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PSORALEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ARTHRITIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; LOW DRUG DOSE; MEDICAL RESEARCH; MONOTHERAPY; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; CHILD; DRUG ANTAGONISM; IMMUNOLOGY;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS; ARTHRITIS, JUVENILE RHEUMATOID; ARTHRITIS, PSORIATIC; CHILD; CYTOKINES; HUMANS; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-6; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650129874     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328329ed9f     Document Type: Review

References (42)

1. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for thetreatment of Crohn's disease. N Engl J Med 2007;357:228-238.
2. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to TNF-{alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: the GO-FORWARD Study. Ann Rheum Dis 2008 [Epub ahead of print].
3. Inman RD, Davis JC, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3402-3412.
4. Kavanaugh A, Mease P, Krueger GG, et al. Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study [abstract #671]. In: Program and abstracts of the American College of Rheumatology (ACR) 2008 Annual Scientific Meeting.
5. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-2452.
6. Davis JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-3236.
7. Davis JC, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-352. Important longitudinal safety and efficacy data on the treatment of AS with etanercept.
8. Van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-2146.
9. Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-591.
10. Baraliakos X, Davis J, Tsuji W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor a receptor fusion protein etanercept. Arthritis Rheum 2005;52:1216-1223.
11. Lambert RG, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007;56:4005-4014.
12. Braun J, Landewe R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-1652.
13. McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158.
14. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-320.
15. Oostveen J, Prevo R, den Boer J, et al. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography: a prospective, longitudinal study. J Rheumatol 1999;26:1953-1958.
16. Brandt J, Khariouzov A, Listing J, et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the antitumor necrosis factor - a fusion receptor protein etanercept. J Rheumatol 2004;31:531-538.
17. Brandt J, Haibel H, Reddig J, et al. Successful short term treatment of severe undifferentiated spondyloarthropathy with the antitumor necrosis factor-αmonoclonal antibody infliximab. J Rheumatol 2002;29:118-122.
18. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatmento f axial spondyloarthritis without radiographically defined sacroiliitis. Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58:1981-1991. First randomized placebo-controlled trial of anti-TNFαagent in patients with axial spondyloarthritis who did not have definite radiographic criterion for the diagnosis of AS. Important observation that this group of patients can be reliably diagnosed early in their disease course and that approximately 50% of patients can be expected to improve with adalimumab.
19. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor a blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-670.
20. Baraliakos X, Listing J, Rudwaleit M, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007;66:910-915.
21. Appel H, Sieper J. Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics. Curr Rheumatol Rep 2008;10:356-363.
22. Maksymowych W, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 2009;60:93-102. The most recent study with results that support the concept of a relationship between inflammation and ankylosis.
23. van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-1331. The study raises the question of a disconnection between clinical improvement and radiographic progression in patients with AS treated with etanercept.
24. van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-3070. Important observation of no radiographic improvement in patients with AS despite clinical response to treatment with infliximab.
25. Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1999;17: 809-812.
26. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-2272.
27. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-1236.
28. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Results of the double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-3289.
29. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). J Rheumatol 2008;35:869-876 The efficacy results for all end points for improvement of both psoriasis and PsA in the IMPACT2 study confirm those reported previously in the IMPACT study.
30. Saad AA, Symmons DPM, Noyce PR, et al. Risks and benefits of tumor necrosis factor - a inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-890
31. Kavanaugh A, ANtoni CE, Gladman D, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-1043.
32. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-488.
33. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498-505.
34. Ilowite NT. Update on biologics in juvenile idiopathic arthritis. Curr Opin Rheumatol 2008;20:613-618.
35. Tynjala P, Lahdenne P, Vahasalo P, et al. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 2006;65:1044-1049.
36. Siminini G, Giani T, Stagi S, et al. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology 2005;44:777-780.
37. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-769.
38. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359: 810-820. This randomized, double-blind, stratified, placebo-controlled, multicenter study evaluated efficacy and safety of adalimumab in juvenile idiopathic arthritis, using a 16-week open-label lead-in phase, 32-week double-blind withdrawal phase, and open-label extension phase. The study was not powered to determine differences between patients using or not using MTX.
39. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-1504. Despite the low number of patients, the study gives important information on safety of anti-TNFαtherapy for longer periods of time.
40. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-3106.
41. Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-550.
42. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-324.